- 1 Novel mutation leading to splice donor loss in a conserved site of *DMD*
- 2 causes cryptorchidism
- 3 Jianhai Chen^{1,2,#}, Yangying Jia^{1,2}, Jie Zhong¹, Kun Zhang³, Hongzheng Dai⁴,
- 4 Guanglin He⁵, Fuping Li^{6,#}, Li Zeng^{7,#}, Chuanzhu Fan^{8,#}, Huayan Xu^{3,#}
- 5 Department of Ecology and Evolution, The University of Chicago, 1101E 57th
- 6 Street, Chicago, Illinois 60637, USA
- 7 ²Institutes for Systems Genetics, Frontiers Science Center for Disease-related
- 8 Molecular Network, West China Hospital, Sichuan University, Chengdu
- 9 610041, P.R. China
- 10 ³Department of Radiology, Key Laboratory of Birth Defects and Related
- 11 Diseases of Women and Children of Ministry of Education, West China
- 12 Second University Hospital, Sichuan University, Chengdu 610041, P.R. China
- 13 ⁴Department of Molecular and Human Genetics, Baylor College of Medicine,
- 14 Houston, Texas 77030, USA
- 15 ⁵Institute of Rare Diseases, West China Hospital of Sichuan University,
- 16 Sichuan University, Chengdu, 610044 China
- 17 ⁶Laboratory of Molecular Translational Medicine, Center for Translational
- 18 Medicine, Key Laboratory of Birth Defects and Related Diseases of Women
- 19 and Children (Sichuan University), Ministry of Education, Clinical Research
- 20 Center for Birth Defects of Sichuan Province, West China Second University
- 21 Hospital, Sichuan University, Chengdu, 610041, P.R. China
- ⁷The Department of Pediatric Surgery, West China Hospital, Sichuan
- 23 University, Chengdu 610041, China
- 24 *Department of Biological Sciences, Wayne State University, Detroit, Michigan,
- 25 48202, USA

- [#]Corresponding author: jianhaichen@uchicago.edu; xuhuayan89@sina.com;
- 27 zengli998@163.com; ex3922@wayne.edu; lfpsnake@scu.edu.cn

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

weeks.

Abstract Background As one of the most common congenital abnormalities in male births, cryptorchidism has been found to have a polygenic etiology according to previous studies of common variants. However, little is known about genetic predisposition of rare variants for cryptorchidism, since rare variants have larger effective size on diseases than common variants. **Methods** In this study, a cohort of 115 Chinese probands with cryptorchidism was analyzed using whole-genome sequencing (WGS), alongside 19 parental controls and 2136 unaffected men. Additionally, CRISPR-Cas9 editing of a conserved variant was performed in a mouse model, with MRI screening utilized to observe the phenotype. Results In 30 of 115 patients (26.1%), we identified four novel genes (ARSH, DMD, MAGEA4, and SHROOM2) affecting at least five unrelated patients and four known genes (USP9Y, UBA1, BCORL1, and KDM6A) with the candidate rare pathogenic variants affecting at least two cases. Burden tests of rare variants revealed the genome-wide significances for newly identified genes (p. < 2.5x10⁻⁶) under the Bonferroni correction. Surprisingly, novel and known genes were mainly from X chromosome (seven on X and one on Y) and all rare X-chromosomal segregating variants exhibited a maternal inheritance rather than de novo origin. CRISPR-Cas9 mouse modeling of a splice donor loss variant in DMD (NC_000023.11:g.32454661C>G), which resides in a conserved site across vertebrates, replicated bilateral cryptorchidism phenotypes, confirmed by Magnetic resonance imaging (MRI) at 4 and 10

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Conclusion Our results revealed the role of the *DMD* gene mutation in causing cryptorchidism. The results also suggest that maternal-X inheritance of pathogenic defects could have a predominant role in the development of cryptorchidism. **Keywords**: molecular diagnosis; WGS; rare variants; male-specific disease; male hemizygosity Introduction Cryptorchidism (also known as 'hidden testicle', OMIM 219050) has a global prevalence rate of 2% to 4% at full-term birth in boys ¹. Despite its relatively low prevalence, cryptorchidism is the most common birth defect involving urogenital abnormalities in newborn boys. It is also the best-characterized risk factor for infertility and testicular cancer ². Normally, the testes spontaneously descend into the scrotum by the eighth month (33 weeks) of pregnancy, likely triggered by transient activation of the hypothalamus-pituitary-gonadal (HPG) axis, leading to an increase in reproductive hormone levels ³⁴. In patients with cryptorchidism, one or both testes may fail to descend completely into the dependent part of the scrotum, resulting in unilateral or bilateral cryptorchidism, respectively. Maternal risk factors before and during pregnancy, such as maternal smoking, endocrine-disrupting chemicals, and gestational diabetes, have increasingly been recognized as the risk factors for congenital cryptorchidism ⁵. However, the studies on genetic risk factors of cryptorchidism are still limited. Multiple etiological features, such as familial aggregation and increased prevalence in

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

first-degree relatives, suggest a genetic predisposition to this disease ⁶. For instance, a family history of cryptorchidism can increase the risk of the condition in newborn boys by approximately threefold ⁷⁸. The recurrence risk has been found to be more than twice as high in brothers of cryptorchidism cases compared to healthy controls ⁹. Thus, despite cryptorchidism's complex susceptibility to maternal and environmental factors, strong genetic components may also contribute to its etiology. Previous microarray studies based on common variants (GWAS) have suggested a potential association of certain pathways with cryptorchidism but failed to identify specific genes, likely due to the small effect size of common variants ¹⁰. Indeed, both population genetics theory and empirical data suggest that rare variants have much larger effect sizes than common variants ¹¹⁻¹⁴, indicating their significant role in causing genetic diseases. It is estimated that most human rare protein-altering variants (missense) are pathogenic ¹⁵. Furthermore, disruptive mutations (nonsense) are disproportionately common causal factors in about 11.5% of human genetic diseases ¹⁶. At the population level, these causal variants are rare in allele frequency due to strong purifying selection, which limits their accumulation across generations. Therefore, rare deleterious variants with large genetic effect sizes represent a promising area for discovering causative genes for genetic diseases ¹⁷, especially for diseases affecting fertility, such as cryptorchidism. The application of various genetic screening techniques, including wholegenome and exome sequencing (WGS/WES), has facilitated the precise

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

diagnosis of numerous genetic diseases caused by rare variants ¹⁸⁻²⁵. For instance, a WES study on an Indian family identified a rare deleterious homozygous missense variant in the RXFP2 gene, which causes cryptorchidism ²⁶. Although WES is more commonly used than WGS due to its lower cost, WGS offers a more uniform distribution of sequencing quality (including single-nucleotide variants, insertions, and deletions) and a higher discovery rate of coding-region variants, approximately 3%^{27 28}. To date, a rare variants study of cryptorchidism based on WGS is still lacking. In this study, we conducted rare variants screening based on WGS data for 134 Han Chinese samples including cases (115) and family controls (19). We also used a local cohort of 2136 unaffected men for comparison. We identified candidate rare pathogenic variants based on autosomal recessive, compound heterozygous, and X-linked recessive inheritance mode for cryptorchidism patients. We annotated these variants and recognized both known and novel candidate genes and variants. We also confirmed the role of a noval rare mutation in *DMD* (NC 000023.11:q.32454661C>G) in causing cryptorchidism based on transgenic mouse modeling. Our study may facilitate the development of molecular diagnosis and precision medicine for patients suffering from cryptorchidism. Results The MRI on typical bilateral and unilateral cryptorchidism and basic sequencing statistics.

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

The diagnosis of cryptorchidism was based on a physical exam by professional pediatric urologists following standard protocols ²⁹. Typical bilateral cryptorchidism and unilateral cryptorchidism of two patients were shown using the magnetic resonance imaging (MRI) (Figure 1a-1d). In comparison to controls, the patient with bilateral cryptorchidism had two nondescended testes, while the patient with unilateral cryptorchidism had only one undescended testis (Figure 1). We conducted WGS on 115 cases and 19 family controls. Among the cases, there were 21 (18.26%) bilateral cryptorchidism patients and 94 (81.74%) unilateral cryptorchidism patients. This dataset also includes three family trios of bilateral cryptorchidism, four trios of unilateral cryptorchidism, and three duos with only cryptorchidism cases and mothers. Based on previous sensitivity tests, 15x WGS depth/fold can achieve accurate SNV calling, while 30x is sufficient for calling indels ^{30 31}. In this study, the average sequencing depths were 33.03-fold for cases and 27.97-fold for controls, suggesting a balanced design of sequencing depth and quality for all samples (Supplementary Table 1, Figure 1f and Supplementary Figure 1a). To confirm the reported relationship, we used whole-genome SNPs to estimate the relatedness between family members. We also confirmed the population ancestry of all samples based on the principal component analysis (PCA). Based on identity by state (IBS) distances among family members, we confirmed that family members are genetically closer than unrelated individuals (Supplementary Figure 1b). We also confirmed that all parents-son relationships are within the coefficient range of first-degree relatives (from 0.177 to 0.354). By incorporating individuals from the "1000 genomes" project, we further revealed that all newly sequenced samples are closely related to the East Asian population (Supplementary Figure 1c).

The Rare Candidate Pathogenic Variants for Known Genes

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

With the keywords 'cryptorchidism variants' and 'cryptorchidism genetics', we conducted the initial screening for known genes in the PubMed literature database ³². We retrieved 56 genes previously reported to be associated with cryptorchidism (Supplementary Table 2). Most of these previous studies were based on the genetic screening of small patient samples. Thus, it is interesting to know whether these genes can be confirmed in our cohort. We found that 41 of these genes were also registered in the Online Mendelian Inheritance in Man (OMIM) and Human Phenotype Ontology (HPO) database (June-2022) as genes related to cryptorchidism. We also added 738 genes associated with cryptorchidism phenotypes from these databases. These 779 genes (738+41) were used as a "pool" of known genes (Supplementary Table 2). We annotated non-redundant variants using the online tool VEP in the Ensembl database ³³ and then summarized both known and novel candidate genes. We detected four known genes (BCORL1, KDM6A, UBA1, and USP9Y) with candidate rare pathogenic variants present in at least two cases but absent in paternal controls (Table 1 and Supplementary Table 3). Six variants were not

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

detected in all publicly available population databases (gnomAD, 1000 genomes, dbSNP, ExAC, ClinVar, etc.). One variant, BCORL1 (NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)), was also classified as rare based on the allele frequency of all human populations, with the highest frequency in East Asian population (0.005439; Supplementary Table 3). Although this allele frequency is relatively higher in the East Asian population than globally, it remains much lower than the global prevalence rate of cryptorchidism in boys, which is 2%-4%. Interestingly, all known genes affecting at least two cases are on sex chromosomes. Not a single autosomal gene was associated with more than one case. This strongly suggests a predominant role of sex chromosomal genes in cryptorchidism pathogenicity. The Y-chromosome gene USP9Y (Ubiquitin Specific Peptidase 9 Y-Linked) was detected in six boys with unilateral cryptorchidism. In addition, three X-chromosome genes (BCORL1, UBA1, and KDM6A) were found to carry candidate rare pathogenic variants affecting at least two patients. Strikingly, the two rare pathogenic variants in BCORL1 (NC_000023.11:g.130028727G>A; NP_001171701.1:p.(G1391R)) and USP9Y (NC_000024.10:g.12739592C>G; NP_004645.2:p.(S462C)) were found in four unilateral patients per variant, with only the former registered in the gnomAD database. Both variants were predicted to be deleterious by multiple in silico algorithms (Supplementary Table 3). In addition, the wild-type

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

alleles of these variants showed evolutionary conservation in primate species, based on sequence alignments of primate orthologous genes from the Ensembl database (v105, Supplementary Figure 2). Together, the candidate rare pathogenic variants of known genes were found to affect 12 cases, indicating a molecular diagnostic rate of 10.4% (12/115). The diagnostic rates for bilateral and unilateral cryptorchidism were 0% (0/21) and 12.77% (12/94). respectively. These candidate pathogenic variants and genotypes in cases and parents were validated using the Sanger Sequencing (Supplementary Figure 3). The Rare Candidate Pathogenic Variants for Novel Genes To identify candidate pathogenic variants in novel candidate genes for cryptorchidism, we excluded cases with the above-mentioned pathogenic variants in known genes. Subsequently, we ranked genes based on the burden of rare deleterious variants that occurred in cases. To increase the reliability of the newly identified genes, we focused on genes affecting at least five cases with candidate variants. We found four genes that fulfilled these rigorous requirements: DMD, ARSH, MAGEA4, and SHROOM2 (Table 2). Based on allele frequencies in multiple genome databases (gnomAD, 1000 genomes, dbSNP, ExAC, ClinVar, etc.) and in silico predictions, all variants

were classified as 'rare' based on allele frequencies in normal populations

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

(allele frequency < 0.01) and classified as 'deleterious' by at least one prediction method. The candidate pathogenic variants of these novel genes were found in 20 cases but not in paternal controls, nor in a local cohort of 2136 healthy men (Supplementary Table 4). Moreover, the wild-type alleles showed a primate-wide evolutionary conservation based on the Ensembl sequence alignments of orthologous genes (Supplementary Figure 4). Interestingly, a splice donor variant in *DMD* (NC_000023.11:g.32454661C>G) is located in a site highly conserved across vertebrates, ranging from mammals to birds, reptiles, and fish (Figure 3). The cases U27 and U55 both had two candidate variants. Among the affected cases, four were bilateral and involved in genes ARSH, DMD, and SHROOM2. The remaining 16 unilateral cases were affected by all four genes. Thus, the diagnostic rates for bilateral and unilateral cryptorchidism are 19.05% (4/21) and 17.02% (16/94), respectively. Together with the known genes, the overall diagnostic rates are 23.81% (5/21) and 28.72% (27/94) for bilateral and unilateral cryptorchidism, respectively. Based on gnomAD records, five variants showed low allele frequencies in both the global and East Asian population, while the remaining ten variants were newly discovered without information on allele frequency in databases (Supplementary Table 4). We also found recurrent variants in multiple cases: NC_000023.11:g.32346044G>C; NP_000100.2:p.(Q1821E) (DMD, two

229 patients), NC 000023.11:g.3033050C>G; NP 001011719.1:p.(P452A) 230 (ARSH, three patients), NC_000023.11:g.151924064G>A; 231 NP 001011550.1:p.(A134T) (MAGEA4, four patients), and 232 NC_000023.11:g.9937537G>T; NP_001307593.1:p.(A166S) (SHROOM2, two 233 patients). These candidate variants and genotypes were also validated using 234 the Sanger Sequencing for all samples (Supplementary Figure 5). 235 Burden Tests Support the Statistical Significance of Novel Candidate 236 genes 237 To statistically test our newly identified candidate genes, we performed burden tests for rare variants with the RVTEST package ³⁴. We further used 238 239 Bonferroni correction to account for multiple testing ($p = 2.5 \times 10^{-6}$). We found 240 that five tests supported the whole-genome significance of three genes DMD. 241 MAGEA4, and SHROOM2 (Table 3, p < 2.5×10^{-6}). For ARSH, four methods, 242 except for the CMC Wald test, supported the genome-wide significance after 243 Bonferroni correction (p < 2.5×10^{-6}). 244 The Maternal Origin of Candidate Variants of X-chromosome Genes 245 We identified 20 candidate X-chromosomal variants from known and novel 246 genes affecting at least two cases, based on variant screening results 247 (Supplementary Tables 3 and 4). There are two possibilities for the origin of 248 these variants: de novo mutation during the early embryonic development of 249 probands or during maternal oogenesis and the maternal X inheritance. For 250 the de novo mutation hypothesis, we would not expect to find the variant in

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

maternal genotypes. For the maternal X inheritance mode, we would detect heterozygotes in maternal samples. In the seven trios with WGS data, the candidate variant NC_000023.11:g.151924064G>A; NP_001011550.1:p.(A134T) in MAGEA4 was detected only in proband U8 (Supplementary Table 4). The Sanger Sequencing of these variants in trios indicated a maternal X-chromosome origin (Figure 2a). For the duo of U9 and 9M samples, we also observed maternal heterozygotes in the X-chromosomal variant genotype, despite the unavailability of the paternal sample. For the additional trios with WGS-only probands, the Sanger Sequencing of parental samples confirmed the maternal X inheritance, in which X hemizygotes, maternal heterozygotes, and paternal wild types were found simultaneously in all trios (Figure 2). Together, the Sanger Sequencing of four variants, which affected seven cases and parents, supported the maternal X-chromosome origin exclusively, rather than de novo mutation from probands' embryogenesis or maternal germline. Future studies based on more pedigree data are needed to further evaluate the probability of *de novo* mutation during oogenesis of maternal germline or early development of probands. No Reliable Compound Heterozygous Rare Variants Were Detected For compound heterozygous mode in autosomes, the family-based structure can facilitate tracing of the parental origin for each rare variant. We firstly focused on two heterozygous rare variants with disruptive effects on proteins for patients of the seven complete trio families. Then, we relaxed the criteria

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

of variant impacts to cover the scenario of one heterozygous rare variant with disruptive effect and the other with moderate impact (sequence-altering). We did not find any gene fulfilling the requirements. Finally, we focused on the scenario of potential compound heterozygous mode, in which non-pedigree probands would carry at least two heterozygous rare variants in a gene with disruptive effects. We observed two heterozygous rare variants of RPTN with stop-gain and frameshift impacts in four unrelated patients (Supplementary Table 5). However, the two variants had the same allele frequency in all super-populations in the gnomAD database, suggesting that they are more likely to be inherited via the linkage disequilibrium, rather than the real compound heterozygous variants. CRISPR-Cas9 mouse modeling of the splice donor variant in *DMD* (NC_000023.11:g.32454661C>G) Considering the highly conserved nature of the wild-type splice donor variant in DMD (NC_000023.11:g.32454661C>G, represented as 'C' in Figure 3a-3b), we generated transgenic mice with the mutant variant ('G') using the CRISPR-Cas9 editing technique (Figure 3c). We examined cryptorchidism phenotypes in F2 male mice using MRI at weeks 4 and 10. In the DMD transgenic mice, we found undescended testicles that are different from the wild-type mice of the same age (Figure 3d). The undescended testicles were located in the inguinal region, suggesting the involvement of the *DMD* gene in the development of cryptorchidism.

Discussion

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

In this study, we conducted rare variants screening for cryptorchidism in humans. Among the known genes related to cryptorchidism, the mutation burden and rigorous filtering of rare and predicted deleterious variants support the roles of USP9Y, KDM6A, BCORL1, and UBA1 in the pathogenicity of cryptorchidism. USP9Y is one of the three genes within an azoospermia factor (AZFa) region. Previous studies have revealed that USP9Y showed increased transcript levels in patients suffering from cryptorchidism after a treatment with the gonadotropin-releasing hormone agonist GnRHa ³⁵. Exome sequencing has revealed the role of BCORL1 in spermatogenesis 36. UBA1 has been reported in patients with Spinal Muscular Atrophy 2 and cryptorchidism ³⁷. KDM6A is related to the Kabuki syndrome, which may involve hypospadias and cryptorchidism in males ³⁸. However, most of these studies were not designed specifically for investigating cryptorchidism-associated genes and variants, so our study expands the phenotypic spectrum of these gene defects. More importantly, we identified four novel candidate cryptorchid genes (DMD, ARSH, MAGEA4, and SHROOM2) with genome-wide significant burdens of rare mutations with both disruptive and sequence-altering impacts. The gene MAGEA4 (melanoma antigen family A, 4) is commonly used as a marker for human spermatogonia ³⁹. Based on the immunohistochemistry of *MAGEA4*, the number of spermatogonia was decreased in cryptorchid testes compared to the normal testes ⁴⁰. Although poorly characterized, the gene *SHROOM2*

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

was reported in patients with infertility ⁴¹. Notably, the findings of the pathogenic variants of *DMD* are particularly interesting, because of the established role of *DMD* in producing the protein dystrophin critical for muscle development ⁴². Clinical studies have revealed a positive correlation (OR, 2.83) between the urogenital malformation and muscular disorders, possibly due to muscular defects in the cremaster muscle or other inquinal tissues 43. DMD defects have been reported extensively in Duchenne/Becker muscular dystrophy 44 45. Considering the dynamic process involving the muscular traction of the gubernaculum during the normal testes descendance ⁴⁶, our study suggests that muscular abnormalities may play a major role in cryptorchidism. As the maternal effect is higher than the paternal effect for cryptorchidism (for example, the recurrence rate is higher in maternal half-brothers than in paternal half-brothers), the possibility of maternal inheritance has long been suspected ^{9 47}. In this study, we revealed the genetic basis of maternal inheritance of cryptorchidism by finding the dominant role of X-chromosomal genes and their maternal origin. Indeed, based on the pedigree-based Sanger sequencing, we revealed that some X-chromosomal variants with available parental samples were inherited from maternal rather than paternal lineages. This result is consistent with the expectation of both the X-hemizygosity effect and the nature of male-specific disease. Because of X-hemizygosity in males, X-chromosomal pathogenic variants invariably affect the males, while commonly being masked by a normal allele in heterozygous females. In

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

addition, the causative variant for a male-specific trait would affect males more heavily than females, except in case of a pleiotropic effect of the variant on both sexes. Clinically, such hereditary pattern could be utilized to screen those sex-related genetic disorders in male humans and to develop subsequent prevention and therapeutic measurements. Together, among the total of eight known and novel genes affecting multiple unrelated patients of cryptorchidism, seven are X-chromosomal genes and one is a Y gene. The candidate variants of X-chromosomal genes follow the expectation of maternal inheritance rather than de novo mutation. Thus, our study revealed a predominant role of sex chromosomal, and particularly the X-chromosomal, gene defects, in causing male cryptorchidism. Conclusion We identified rare pathogenic variants of four known candidate genes (USP9Y, UBA1, BCORL1, and KDM6A) and four novel candidate genes (ARSH, DMD, *MAGEA4*, and *SHROOM2*) in patients suffering from cryptorchidism. Considering the chromosomal distribution, seven out of eight genes are within the X-chromosome, and *USP9Y* is located on the Y-chromosome. This reveals a predominant role of X-chromosomal genes in cryptorchidism. The maternal origin of these X-chromosomal variants reflects the strong effect of X-hemizygosity on male-specific diseases. We successfully replicated

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

cryptorchidism phenotypes in transgenic mice. These mice harbor a splice donor loss variant in DMD (NC_000023.11:g.32454661C>G), establishing a viable mouse model for future research and therapy studies of this condition. **Materials and methods** DNA samples, patient background, and whole-genome sequencing DNA was extracted from peripheral whole blood of 115 patients and 19 parental controls, using a local database of variants from 2136 unaffected men for subsequent comparison. The patients were diagnosed by pediatric specialists of the West China Hospital (WCH) and West China Second University Hospital (WCSUH). The parents were carefully inquired about family history and all fathers denied the existence of cryptorchidism in the family history. All participating parents provided informed consent, and this study was formally approved by the ethics committees of WCH (Registration number: 2021389) and WCSUH (Registration number: 2021389). The WGS (150 bp paired-end) data of an insert size of 350 bp were sequenced using the DNBSEQ-T7 platform (MGI), according to the manufacturer's protocol (Supplementary Table 1). Variants calling, genotyping, and annotation Based on the high-performance computing system, we locally conducted the variant calling, genetic relationship, and population ancestry using the pipeline described previously ⁴⁸⁻⁵⁰. The rare variants were defined as alleles with frequency lower than 0.01 in all geographic human populations of gnomAD

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

v3.1. Pathogenic variants were identified for known and novel genes (Supplementary note). Validation of variants and genotypes using the Sanger sequencing Following the identification of candidate rare pathogenic variants, the Sanger sequencing was conducted for all probands at first to remove false positive variants due to errors in NGS sequencing or calling process. For the validated variants in probands, we further conducted the Sanger sequencing for all available parental samples, including samples from additional six trios in which only probands had WGS data. The parental genotypes were further used to evaluate the origin of variants. The C56BL/6J transgenic mouse modeling For the highly conserved variant, transgenic mouse was modeled using the CRISPR-Cas9 editing technique. Briefly, the process was carried out in two main stages: the in vitro stage and the in vivo stage. In the in vitro stage, the process began with the design and construction of guide RNAs (gRNAs) specific to the target DNA sequence around variant, followed by the design and construction of the donor vector, which carried the desired genetic modification. The in vivo stage involved microinjecting the designed gRNA and donor vector into fertilized eggs, and then transplanting these embryos into surrogate mothers. This led to the birth of the F0 generation mice, which were subsequently screened to identify individuals with successful genetic

modifications. Positive F0 generation mice were then bred to produce the F1

generation, and these offspring were also screened to confirm the presence of

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

the genetic modification. The F2 mice were examined for phenotypes with MRI (Time Medical Systems, Inc., USA). **Statements & Declarations** Acknowledgements This study was supported by the fifth batch of technological innovation research projects in Chengdu (2021-YF05 -01331-SN), the Postdoctoral Research and Development Fund of West China Hospital of Sichuan University (2020HXBH087), the Short-Term Expert Fund of West China Hospital (139190032), Fund of Sichuan Provincial Department of Science and Technology (2021YFS0244), and Fund of Sichuan Provincial Department of Science and Technology (2021YFS0026). We also acknowledge the computing support from the West China Biomedical Big Data Center and the Med-X Center for Informatics of Sichuan University. **Competing Interests** The authors declare no competing financial interests. **Author Contributions** H.Y.X., C.Z.F., L.Z., and F.P.L. supervised this work. J.H.C., J.Z., K.Z., and H.Z.D., designed the research. J.H.C., J.Z., and GL.H analyzed data. J.H.C, Y.Y.J, and J.Z. conducted lab work. G.L.H provided the candidate rare

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

variants screening in 2136 normal controls. J.H.C. drafted the manuscript and all authors took part in revising and improving the manuscript. **Data Availability** The candidate variants data are listed in the supplementary tables. The variants data could be available from the corresponding author on request. **Ethics approval** All authors declare that they have no Conflict of Interest. This study conformed with the Helsinki Declaration of 1975 (as revised in 2008) concerning Human and Animal Rights. All participating parents provided informed consent, and this study was formally approved by the ethics committees of WCH (Registration number: 2021389) and WCSUH (Registration number: 2021389). Consent to participate Written informed consent was obtained from the parents. References 1. Barthold JS, González R. The Epidemiology of Congenital Cryptorchidism, Testicular Ascent and Orchiopexy. Journal of Urology 2003;170(6):2396-401. doi: doi:10.1097/01.ju.0000095793.04232.d8 2. Agoulnik A, Ferguson L. Testicular Cancer and Cryptorchidism. 2013;4 doi: 10.3389/fendo.2013.00032 3. Kuiri-Hänninen T, Koskenniemi J, Dunkel L, et al. Postnatal Testicular Activity in Healthy Boys and Boys With Cryptorchidism. Frontiers in Endocrinology 2019;10 doi: 10.3389/fendo.2019.00489 4. Raivio T, Toppari J, Kaleva M, et al. Serum Androgen Bioactivity in Cryptorchid and Noncryptorchid Boys during the Postnatal Reproductive Hormone Surge. The Journal of Clinical Endocrinology

& Metabolism 2003;88(6):2597-99. doi: 10.1210/jc.2002-021676

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

5. Elamo HP, Virtanen HE, Toppari J. Genetics of cryptorchidism and testicular regression. Best Practice & Research Clinical Endocrinology & Metabolism 2022;36(1):101619. doi: https://doi.org/10.1016/j.beem.2022.101619 6. Chacko JK, Barthold JS. Genetic and environmental contributors to cryptorchidism. Pediatr Endocrinol Rev 2009;6(4):476-80. 7. Elert A, Jahn K, Heidenreich A, et al. Population-based investigation of familial undescended testis and its association with other urogenital anomalies. Journal of Pediatric Urology 2005;1(6):403-07. doi: 10.1016/j.jpurol.2005.04.005 8. Promm M, Schröder A, Neissner C, et al. Acquired cryptorchidism: More harm than thought? Journal of Pediatric Urology 2016;12(4):236.e1-36.e6. doi: 10.1016/j.jpurol.2016.04.010 9. Schnack TH, Zdravkovic S, Myrup C, et al. Familial aggregation of cryptorchidism—a nationwide cohort study. 2008;167(12):1453-57. 10. Barthold JS, Wang Y, Kolon TF, et al. Pathway analysis supports association of nonsyndromic cryptorchidism with genetic loci linked to cytoskeleton-dependent functions. Human Reproduction 2015;30(10):2439-51. doi: 10.1093/humrep/dev180 11. Bloom JS, Boocock J, Treusch S, et al. Rare variants contribute disproportionately to quantitative trait variation in yeast. eLife 2019;8:e49212. doi: 10.7554/eLife.49212 12. Walter K, Min JL, Huang J, et al. The UK10K project identifies rare variants in health and disease. Nature 2015;526(7571):82-90. doi: 10.1038/nature14962 13. Maher MC, Uricchio LH, Torgerson DG, et al. Population Genetics of Rare Variants and Complex Diseases. Human Heredity 2012;74(3-4):118-28. doi: 10.1159/000346826 14. Halvorsen M, Huh R, Oskolkov N, et al. Increased burden of ultra-rare structural variants localizing to boundaries of topologically associated domains in schizophrenia. Nature Communications 2020;11(1):1842. doi: 10.1038/s41467-020-15707-w 15. Kryukov GV, Pennacchio LA, Sunyaev SR. Most Rare Missense Alleles Are Deleterious in Humans: Implications for Complex Disease and Association Studies. The American Journal of Human Genetics 2007;80(4):727-39. doi: https://doi.org/10.1086/513473 16. Abrahams L, Savisaar R, Mordstein C, et al. Evidence in disease and non-disease contexts that nonsense mutations cause altered splicing via motif disruption. Nucleic Acids Research 2021;49(17):9665-85. doi: 10.1093/nar/gkab750 17. Ganna A, Satterstrom FK, Zekavat SM, et al. Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. The American Journal of Human Genetics 2018;102(6):1204-11. doi: 10.1016/j.ajhg.2018.05.002 18. Li J, Kong N, Han B, et al. Rare variants regulate expression of nearby individual genes in multiple tissues. PLOS Genetics 2021;17(6):e1009596. doi: 10.1371/journal.pgen.1009596

486 19. Gorlov I, Gorlova O, Frazier M, et al. Evolutionary evidence of the effect of rare variants on disease 487 etiology. Clinical Genetics 2011;79(3):199-206. doi: https://doi.org/10.1111/j.1399-488 0004.2010.01535.x 489 20. Wang J, Lu Y, Yan X, et al. Identification of novel MITF mutations in Chinese families with 490 Waardenburg syndrome type ||. Molecular Genetics & Genomic Medicine 2021;9(9):e1770. 491 doi: https://doi.org/10.1002/mgg3.1770 492 21. Bu F, Zhong M, Chen Q, et al. DVPred: a disease-specific prediction tool for variant pathogenicity 493 classification for hearing loss. Hum Genet 2022;141(3-4):401-11. doi: 10.1007/s00439-022-494 02440-1 [published Online First: 20220219] 495 22. Cheng J, Zhou X, Lu Y, et al. Exome sequencing identifies a novel frameshift mutation of MYO6 as 496 the cause of autosomal dominant nonsyndromic hearing loss in a Chinese family. Ann Hum 497 Genet 2014;78(6):410-23. doi: 10.1111/ahg.12084 [published Online First: 20140917] 498 23. Sun Y, Cheng J, Lu Y, et al. Identification of two novel missense WFS1 mutations, H696Y and R703H, 499 in patients with non-syndromic low-frequency sensorineural hearing loss. J Genet Genomics 500 2011;38(2):71-6. doi: 10.1016/j.jcg.2011.01.001 [published Online First: 20110223] 501 24. Cheng J, Zhu Y, He S, et al. Functional mutation of SMAC/DIABLO, encoding a mitochondrial 502 proapoptotic protein, causes human progressive hearing loss DFNA64. Am J Hum Genet 503 2011;89(1):56-66. doi: 10.1016/j.ajhg.2011.05.027 [published Online First: 20110630] 504 25. Yuan Y, Huang D, Yu F, et al. A de novo GJB2 (connexin 26) mutation, R75W, in a Chinese pedigree 505 with hearing loss and palmoplantar keratoderma. Am J Med Genet A 2009;149a(4):689-92. 506 doi: 10.1002/ajmg.a.32461 507 26. Ayers K, Kumar R, Robevska G, et al. Familial bilateral cryptorchidism is caused by recessive 508 variants in RXFP2. Journal of medical genetics 2019;56(11):727-33. 509 27. Belkadi A, Bolze A, Itan Y, et al. Whole-genome sequencing is more powerful than whole-exome 510 sequencing for detecting exome variants. Proceedings of the National Academy of Sciences 511 2015;112(17):5473-78. doi: doi:10.1073/pnas.1418631112 512 28. Hiatt SM, Thompson ML, Prokop JW, et al. Deleterious Variation in BRSK2 Associates with a 513 Neurodevelopmental Disorder. The American Journal of Human Genetics 2019;104(4):701-08. 514 doi: 10.1016/j.ajhg.2019.02.002 515 29. McDougal WS, Wein AJ, Kavoussi LR, et al. Campbell-Walsh Urology 11th Edition Review E-Book: 516 Elsevier Health Sciences 2015. 517 30. Sun Y, Liu F, Fan C, et al. Characterizing sensitivity and coverage of clinical WGS as a diagnostic test 518 for genetic disorders. BMC Medical Genomics 2021;14(1):102. doi: 10.1186/s12920-021-519 00948-5

520 31. Kishikawa T, Momozawa Y, Ozeki T, et al. Empirical evaluation of variant calling accuracy using 521 ultra-deep whole-genome sequencing data. Scientific Reports 2019;9(1):1784. doi: 522 10.1038/s41598-018-38346-0 523 32. Canese K, Weis S. PubMed: the bibliographic database. The NCBI handbook 2013;2(1) 524 33. McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome biology 525 2016;17(1):1-14. 526 34. Zhan X, Hu Y, Li B, et al. RVTESTS: an efficient and comprehensive tool for rare variant association 527 analysis using sequence data. Bioinformatics 2016;32(9):1423-26. 528 35. Gegenschatz-Schmid K, Verkauskas G, Stadler MB, et al. Genes located in Y-chromosomal regions 529 important for male fertility show altered transcript levels in cryptorchidism and respond to 530 curative hormone treatment. Basic and Clinical Andrology 2019;29(1):8. doi: 531 10.1186/s12610-019-0089-3 532 36. Lu C, Zhang Y, Qin Y, et al. Human X chromosome exome sequencing identifies BCORL1 as 533 contributor to spermatogenesis. Journal of Medical Genetics 2021;58(1):56-65. doi: 534 10.1136/jmedgenet-2019-106598 535 37. Öztürk Ö, Çavdartepe BE, Bağış H. X-Linked Spinal Muscular Atrophy 2 due to a Synonymous 536 Variant in the UBA1 Gene in a Family with Novel Findings from Turkey. Molecular 537 Syndromology 2022;13(3):246-53. doi: 10.1159/000519640 538 38. Armstrong L, Moneim AAE, Aleck K, et al. Further delineation of Kabuki syndrome in 48 well-539 defined new individuals. American Journal of Medical Genetics Part A 2005;132A(3):265-72. 540 doi: https://doi.org/10.1002/ajmg.a.30340 541 39. He Z, Kokkinaki M, Jiang J, et al. Isolation, Characterization, and Culture of Human 542 Spermatogonia1. Biology of Reproduction 2010;82(2):363-72. doi: 543 10.1095/biolreprod.109.078550 544 40. Yang S, Ping P, Ma M, et al. Generation of Haploid Spermatids with Fertilization and Development 545 Capacity from Human Spermatogonial Stem Cells of Cryptorchid Patients. Stem Cell Reports 546 2014;3(4):663-75. doi: 10.1016/j.stemcr.2014.08.004 547 41. Fabian-Jessing BK, Vestergaard EM, Plomp AS, et al. Ocular albinism with infertility and late-onset 548 sensorineural hearing loss. 2018;176(7):1587-93. doi: https://doi.org/10.1002/ajmg.a.38836 549 42. Duan D, Goemans N, Takeda Si, et al. Duchenne muscular dystrophy. Nature Reviews Disease 550 Primers 2021;7(1):13. doi: 10.1038/s41572-021-00248-3 551 43. Diniz G, Barutcuoglu M, Unalp A, et al. Evaluation of the relationship between urogenital 552 abnormalities and neuromuscular disorders Evaluation of the relationship between 553 urogenital abnormalities and. 2008;13(1-2):19-24. 554 44. Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Human 555 genetics 1984;66(1):17-40.

556 45. Emery AE, Muntoni F, Quinlivan R. Duchenne muscular dystrophy: Oxford Monographs on Medical 557 G 2015. 558 46. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and Functional Aspects of Testicular Descent and 559 Cryptorchidism*. Endocrine Reviews 1997;18(2):259-80. doi: 10.1210/edrv.18.2.0298 560 47. Jensen MS, Toft G, Thulstrup AM, et al. Cryptorchidism concordance in monozygotic and dizygotic 561 twin brothers, full brothers, and half-brothers. Fertility and Sterility 2010;93(1):124-29. doi: 562 10.1016/j.fertnstert.2008.09.041 563 48. Chen J, Zhang P, Chen H, et al. Whole-genome sequencing identifies rare missense variants of 564 WNT16 and ERVW-1 causing the systemic lupus erythematosus. Genomics 565 2022;114(3):110332. doi: https://doi.org/10.1016/j.ygeno.2022.110332 566 49. Oud MS, Houston BJ, Volozonoka L, et al. Exome sequencing reveals variants in known and novel 567 candidate genes for severe sperm motility disorders. Human Reproduction 2021;36(9):2597-568 611. doi: 10.1093/humrep/deab099 569 50. Jia Y, Chen J, Zhong J, et al. Novel rare mutation in a conserved site of PTPRB causes human 570 hypoplastic left heart syndrome. Clinical Genetics 2023;103(1):79-86. doi: 571 https://doi.org/10.1111/cge.14234 572 573 Table 1. The candidate pathogenic variants of known genes. "B" and "U" in ID 574 column are "bilateral cryptorchidism" and "unilateral cryptorchidism", 575 respectively. The "Pred" column shows the number of prediction methods 576 that support deleterious effects of the variants (see Supplementary Table 3 577 for specific methods). Note: <u>USP9Y</u> (underlined) is a Y chromosome gene, 578 while all other genes reside on the X chromosome.

ID	HVGS	Gene,Chr	Pred
U106	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	BCORL1	6
U37	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	BCORL1	6
U50	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	BCORL1	6
U9	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	BCORL1	6
U60	NC_000023.11:g.45069958A>C;NP_001278345.1:p.(K775T)	KDM6A	5
U58	NC_000023.11:g.45110152A>G;NP_001278344.1:p.(D1412G)	KDM6A	6
U51	NC_000023.11:g.47212835A>T;NP_003325.2:p.(Y873F)	UBA1	11
U60	NC_000023.11:g.47214843G>C;NP_695012.1:p.(V1031L)	UBA1	5
U49	NC_000024.10:g.12722148G>A;NP_004645.2:p.(E96K)	<u>USP9Y</u>	6
U50	NC_000024.10:g.12722148G>A;NP_004645.2:p.(E96K)	<u>USP9Y</u>	7
U109	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5
U73	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5

U13	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5
U71	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5

Table 2. The pathogenic variants in novel candidate genes. "B" and "U" in the ID column are "bilateral cryptorchidism" and "unilateral cryptorchidism", respectively. The "Pred" column shows the number of prediction methods supporting the variants as deleterious (see Supplementary Table 4 for specific *in silico* prediction algorithms). Note: all genes are on the X chromosome.

ID	HGVSc	Gene	Pred
U27	NC_000023.11:g.3024049G>C;NP_001011719.1:p.(E310D)	ARSH	5
U64	NC_000023.11:g.3024093G>C;NP_001011719.1:p.(G325A)	ARSH	13
B122	NC_000023.11:g.3033050C>G;NP_001011719.1:p.(P452A)	ARSH	9
U127	NC_000023.11:g.3033050C>G;NP_001011719.1:p.(P452A)	ARSH	9
U28	NC_000023.11:g.3033050C>G;NP_001011719.1:p.(P452A)	ARSH	9
U42	NC_000023.11:g.31774145C>T; LRG_199p1:p.(E2453K)	DMD	3
U55	NC_000023.11:g.32342234G>A;NP_004000.1:p.(R1926C)	DMD	6
U114	NC_000023.11:g.32346044G>C;NP_000100.2:p.(Q1821E)	DMD	1
U58	NC_000023.11:g.32346044G>C;NP_000100.2:p.(Q1821E)	DMD	1
B130	NC_000023.11:g.32454661C>G (splice donor loss variant)	DMD	1
U70	NC_000023.11:g.32472199A>G;NP_000100.2:p.(Y964H)	DMD	5
U111	NC_000023.11:g.32573783C>T; NP_000100.2:p.(D548N)	DMD	7
U106	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U36	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U8	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U94	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U27	NC_000023.11:g.151924194A>T;NP_001373127.1:p.(Y177F)	MAGEA4	4
U98	NC_000023.11:g.9786618C>A;NP_001640.1:p.(R25S)	SHROOM2	2
U33	NC_000023.11:g.9894590G>A;NP_001640.1:p.(D228N)	SHROOM2	2
U2	NC_000023.11:g.9937394C>T;NP_001307593.1:p.(P118L)	SHROOM2	5
U55	NC_000023.11:g.9937537G>T;NP_001307593.1:p.(A166S)	SHROOM2	2
B79	NC_000023.11:g.9937537G>T;NP_001307593.1:p.(A166S)	SHROOM2	5
B81	NC_000023.11:g.3024049G>C;NP_001011719.1:p.(E310D)	SHROOM2	5

Table 3. The significance levels of burden tests for novel candidate genes with rare variants.

Gene	CMC	CMCFisherExact	CMCWald	Fp	Zeggini
ARSH	5.90E-20	1.19E-06	2.20E-05	4.12E-21	5.90E-20
DMD	2.01E-38	8.39E-15	3.54E-18	1.32E-52	2.01E-38

MAGEA4	3.11E-65	2.32E-22	7.75E-23	2.25E-18	1.48E-52
SHROOM2	5.41E-32	1.48E-11	6.67E-13	1.40E-46	5.41E-32

Figures legends

Figure 1. The Magnetic Resonance Imaging (MRI) and Sequencing Depth. (a-e) The two magnetic resonance imaging (MRI) graphs for bilateral cryptorchidism (case B130). (c-d) The two MRI graphs for unilateral cryptorchidism (case U111). (e) The MRI for one control. The red arrows show the location of the testes. (f) The WGS overall depths for the cases (red) and control (green).

Figure 2. The Pedigree Information and the Chromatogram of the Sanger Sequencing Results For Cases and Their Parents. (a) The pedigree

information for seven trios and four duos with WGS data. (b) The pedigree information for six trios, with WGS data only for the cases. (c) The Sanger sequencing chromatogram for candidate variants of known and novel genes. "1/1", "0/1", and "0/0" are genotypes. U and B represent "unilateral" and "bilateral", respectively. "F" and "M" indicate "Father" and "Mother", respectively. "-F" and "-R" show the results of PCR sequencing from forward primer and reverse primer, respectively.

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

Figure 3. Evolutionary Conservation of the Splice Donor Variant in *DMD* (NC 000023.11:g.32454661C>G) and MRI of Transgenic and Normal Mice. (a) Conservation of the *DMD* variant (NC_000023.11:g.32454661C>G) according to the UCSC Vertebrate Alignment. (b) Conservation based on the Amniote alignment from the Ensembl database. (c) Schematic representation of a transgenic mouse with CRISPR-Cas9 editing. (d) Position of the testicles in normal C57 mice compared to *DMD* transgenic mice, as determined by MRI. Undescended testicles were observed in the *DMD* transgenic mice at both 4 and 10 weeks, with both testicles located in the inquinal region. Supplementary Figure 1. The Screening and Analyzing Process for Variants. (a) The bioinformatics pipeline for variant calling, filtering, and genotyping with WGS data. (b) The relationship network among all cases and their family members. Thicker lines indicate closer genetic relationships. (c) The PCA for population identity of newly sequenced individuals conducted by incorporating major populations from the "1000 genomes" project, including African (AFR), American (AMR), European (EUR), South Asian (SAS), and East Asian (Chinese Dai in Xishuanagbanna, CDX; Han Chinese in Beijing, CHB; Han Chinese South, CHS; Japanese in Tokyo, Japan, JPT; Kinh in Ho Chi Minh City, Vietnam, KHV) populations. Supplementary Figure 2. The evolutionary conservation of sites for known genes across primate species, based on the Ensembl (v105) sequence alignments of orthologous genes. The arrows show the locations of variants. Supplementary Figure 3. The Sanger sequencing confirmation for known genes (UBA1, USP9Y, KDM6A, and BCORL1) related to cryptorchidism.

Supplementary Figure 4. The evolutionary conservation of sites for novel candidate genes across primate species, based on the Ensembl (v105) sequence alignments of orthologous genes. The arrows show the loci with gene names and variant information.

Supplementary Figure 5. The Sanger sequencing validation of four novel candidate genes (*DMD*, *ARSH*, *MAGEA4*, and *SHROOM2*) related to cryptorchidism (B130 was not tested due to insufficient amount of DNA).





